Infusion-Related Reactions Induced by Cadonilimab (PD-1/CTLA-4 Bispecific Antibody): Seven Case Reports

被引：1

作者：

Liang, Weiting ^{[1
]}

Guo, Zhijun ^{[2
]}

Zhang, Yunhui ^{[1
]}

Yang, Ning ^{[3
]}

Guo, Chenchen ^{[4
]}

Liu, Tao ^{[1
]}

Huang, Hongbing ^{[1
]}

Chen, Zhuojia ^{[1
]}

机构：

[1] Sun Yat Sen Univ Canc Ctr, Guangdong Prov Clin Res Ctr Canc, State Key Lab Oncol South China,Dept Pharm, Guangdong Key Lab Nasopharyngeal Carcinoma Diag &, Guangzhou, Peoples R China

[2] Heyou Meihe Hosp, Dept Pharm, Foshan, Peoples R China

[3] Gen Hosp Southern Theater Command, Dept Oncol, Guangzhou, Peoples R China

[4] Sun Yat Sen Univ, Sch Pharmaceut Sci, Guangzhou, Peoples R China

来源：

CASE REPORTS IN ONCOLOGY | 2024年 / 17卷 / 01期

关键词：

Cadonilimab; Infusion-related reaction; Immune-related adverse reaction; Pretreatment; Infusion rate; MANAGEMENT; TOXICITIES; PD-1;

D O I：

10.1159/000535504

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Introduction: Cadonilimab (AK104) is an innovative human programmed cell death-1 (PD-1)/cytotoxic T lymphocyte antigen-4 (CTLA-4) bispecific antibody. Compared with the combination therapy of PD-1 and CTLA-4 blockers, less cellular toxicity of cadonilimab was significantly manifested. As one of the characteristic adverse effects of cadonilimab, infusion-related reactions (IRRs) represent fever, chills, rash, decreased blood pressure, and other symptoms. Case Presentation: Here, we documented seven cases of IRRs after the administration of cadonilimab. The symptoms of IRRs were relieved after the discontinuation of cadonilimab and the administration of diphenhydramine, dexamethasone, and cimetidine. Notably, 3 patients were able to tolerate the subsequent cadonilimab therapy under the pretreatment. Conclusion: In this study, we discovered that cadonilimab-related IRRs might be lessened or prevented by administering medication and the proper pretreatment and lowering the infusion rate.

引用

页码：361 / 369

页数：9

共 24 条

[1]

[Anonymous], 2020, insert BavencioPackage

[2]

[Anonymous], 2022, Cadonilimab. Package insert

[3] Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline [J].

Brahmer, Julie R. ;

Lacchetti, Christina ;

Schneider, Bryan J. ;

Atkins, Michael B. ;

Brassil, Kelly J. ;

Caterino, Jeffrey M. ;

Chau, Ian ;

Ernstoff, Marc S. ;

Gardner, Jennifer M. ;

Ginex, Pamela ;

Hallmeyer, Sigrun ;

Chakrabarty, Jennifer Holter ;

Leighl, Natasha B. ;

Mammen, Jennifer S. ;

McDermott, David F. ;

Naing, Aung ;

Nastoupil, Loretta J. ;

Phillips, Tanyanika ;

Porter, Laura D. ;

Puzanov, Igor ;

Reichner, Cristina A. ;

Santomasso, Bianca D. ;

Seigel, Carole ;

Spira, Alexander ;

Suarez-Almazor, Maria E. ;

Wang, Yinghong ;

Weber, Jeffrey S. ;

Wolchok, Jedd D. ;

Thompson, John A. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (17) :1714-+

[4] The importance of early identification of infusion-related reactions to monoclonal antibodies [J].

Caceres, Macarena C. ;

Guerrero-Martin, Jorge ;

Perez-Civantos, Demetrio ;

Palomo-Lopez, Patricia ;

Ignacio Delgado-Mingorance, Juan ;

Duran-Gomez, Noelia .

THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2019, 15 :965-977

[5] Human physiological responses to cold exposure: Acute responses and acclimatization to prolonged exposure [J].

Castellani, John W. ;

Young, Andrew J. .

AUTONOMIC NEUROSCIENCE-BASIC & CLINICAL, 2016, 196 :63-74

[6] Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper [J].

Champiat, S. ;

Lambotte, O. ;

Barreau, E. ;

Belkhir, R. ;

Berdelou, A. ;

Carbonnel, F. ;

Cauquil, C. ;

Chanson, P. ;

Collins, M. ;

Durrbach, A. ;

Ederhy, S. ;

Feuillet, S. ;

Francois, H. ;

Lazarovici, J. ;

Le Pavec, J. ;

De Martin, E. ;

Mateus, C. ;

Michot, J. -M. ;

Samuel, D. ;

Soria, J. -C. ;

Robert, C. ;

Eggermont, A. ;

Marabelle, A. .

ANNALS OF ONCOLOGY, 2016, 27 (04) :559-574

[7] Managing premedications and the risk for reactions to infusional monoclonal antibody therapy [J].

Chung, Christine H. .

ONCOLOGIST, 2008, 13 (06) :725-732

[8] Cadonilimab: First Approval [J].

Keam, Susan J. .

DRUGS, 2022, 82 (12) :1333-1339

[9] Safety Profile of Avelumab in Patients With Advanced Solid Tumors: A Pooled Analysis of Data From the Phase 1 JAVELIN Solid Tumor and Phase 2 JAVELIN Merkel 200 Clinical Trials [J].

Kelly, Karen ;

Infante, Jeffrey R. ;

Taylor, Matthew H. ;

Patel, Manish R. ;

Wong, Deborah J. ;

Iannotti, Nicholas ;

Mehnert, Janice M. ;

Loos, Anja H. ;

Koch, Helga ;

Speit, Isabell ;

Gulley, James L. .

CANCER, 2018, 124 (09) :2010-2017

[10] A review of cancer immunotherapy toxicity [J].

Kennedy, Lucy Boyce ;

Salama, April K. S. .

CA-A CANCER JOURNAL FOR CLINICIANS, 2020, 70 (02) :86-104

← 1 2 3 →